Departure. Clinical Miss. Billion: Should You Bet on Pfizer?
Pfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
Uncover the best no annual fee rewards cards available. Get more value from your spending without extra costs!
15,112 articlesPfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
As July approaches, a seasoned investor lays out why Apple sits at the center of their biggest July bet, citing the S...
Morgan Stanley just boosted its payout while re-upping a massive buyback. This article breaks down what the paired di...
Celebrity-driven events are pushing luxury demand and shifting investor sentiment. This report tracks how the taylor ...
A renewed uptrend in Bloom Energy stock has caught investors’ attention. This analysis breaks down the why, how it co...
Two veteran venture partners unveil a method to identify future unicorn founders with momentum, using a four-domain, ...
A new generation rewrites the wealth playbook, stacking income streams and investing smarter as traditional paths gro...
Broadcom’s AI-driven revenue surge is reshaping the chip landscape, prompting persistent buying from a longtime inves...
Nvidia dominates today’s AI data centers, but the real threat to its throne may be a risk that sits in plain sight. T...
Investing in nuclear energy can feel like riding a high-speed train. Oklo’s small modular reactors promise a greener ...
Sandisk stock dropped again as memory-chip demand uncertainty echoed through the market. This guide breaks down why t...
AMD and Nvidia both ride the AI wave, but their scales and strategies differ. This deep dive shows why the stock frac...